

## AngioDynamics Announces Availability of AngioFlow™ Thermal Dilution Catheter and AngioFlow™ Meter in the U.S.

Queensbury, NY, April 20, 2004 – ANGIODYNAMICS, INC., a wholly owned subsidiary of E-Z-EM, Inc., (AMEX: EZM) today announced the introduction of the AngioFlow™ Thermal Dilution Catheter and AngioFlow Meter in the United States, collectively known as the AngioFlow System. The AngioFlow System is a catheter-based flow meter the Company believes will be the first device to measure blood flow in hemodialysis access sites during an access site clearing procedure.

Maintaining the patency of a vascular access graft or fistula is critical to the survival of patients with chronic renal failure. Several studies have determined that a blood flow less than 600ml/min is predictive of a developing stenosis within a graft or fistula. If left untreated, the graft or fistula will occlude, and the patient will be unable to undergo hemodialysis treatment. Multiple endovascular and surgical interventions are frequently required to maintain patency of a vascular access. The AngioFlow System provides accurate and immediate blood flow measurements during these interventions.

Dr. Tom Vesely, an Associate Professor of Radiology, Surgery, and Medicine at the Washington University School of Medicine in Saint Louis, has extensive clinical experience with the AngioFlow system. Commenting on this technology, Dr. Vesely stated, "The AngioFlow system provides valuable and immediate information that is useful for the detection of inconspicuous lesions, optimizing our reparative procedures, and helping to restore full function to the patient's vascular access."

Commenting for AngioDynamics, Don Geer, Director of Marketing for Vascular Access Products, said, "Due to the aging of the population and other factors, the long-term care of patients with chronic renal failure is a growing medical problem. The AngioFlow System helps physicians treat these patients by providing important data on blood flow through the vascular access graft site, and as such represents an important addition to AngioDynamics' dialysis product line. We are pleased to be able to bring this important product to physicians and their patients."

For additional information on the AngioFlow catheter and AngioFlow meter, contact Don Geer at 1-800-772-6446, ext. 167, Email: [dgeer@angiodynamics.com](mailto:dgeer@angiodynamics.com) or visit the AngioDynamics web site at [www.angiodynamics.com](http://www.angiodynamics.com).

### About AngioDynamics

AngioDynamics, Inc. ([www.angiodynamics.com](http://www.angiodynamics.com)) manufactures a wide range of products, including angiographic, dialysis, PTA dilation, thrombolytic, image-guided vascular access, endovascular laser venous system, as well as abdominal infection drainage products. AngioDynamics' focus is on diagnostic and therapeutic products that enable interventional physicians to treat peripheral vascular diseases and other non-coronary diseases.

### About E-Z-EM

E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company has developed the only CT injector on the market that can help detect contrast extravasation, the EmpowerCT® with patented EDA™ technology; it also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system.

The statements made in this document contain certain forward looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance of AngioFlow Thermal Dilution Catheter and AngioFlow Meter, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations, competition, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended February 28, 2004, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company.

Company Contacts:  
AngioDynamics, Inc.  
Lisa Donegan  
(800) 772-6446 x370  
[www.angiodynamics.com](http://www.angiodynamics.com)

Investor Relations Contacts:  
Lippert/Heilshorn & Associates, Inc.

Kim Sutton Golodetz (kgolodetz@lhai.com)  
(212) 838-3777

Bruce Voss (bvoss@lhai.com)  
(310) 691-7100